TICKERNERD
Menu
IRONIRONHealthcare · Biotechnology

IRON Stock Forecast: Disc Medicine, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$70
+0.51% on the day

The 13 Wall Street analysts covering Disc Medicine, Inc. hold a median 12-month price target of $100 — +43.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 18 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$2.7B
Ticker Nerd rank
38 / 100
Median analyst target
$100
Analysts covering
13
Revenue$0.0
Operating income−$65.1M
Net income−$59.5M
Free cash flow−$44.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.8%
1M
−13.3%
YTD
−12.4%
1Y
+11.0%
From 52W high
−26.1%
From 52W low
+24.3%
$56
$94
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IRON stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Disc Medicine, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 18 Sept 2026
38 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
67
Momentum
67
Revisions
66
Value
62
Quality
52
Accruals
39
Size
32
Growth
26
Issuance
16

Volatility (67): The share price has been relatively steady.

Issuance (16): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IRON stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IRON, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$80$100$120$140Oct 25Jan 26Apr 26Jul 26IRONHigh $128Median $100Low $83

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
13 Buy0 Hold0 Sell
Low $83Median $100High $128

The green dot is the last close — the median target sits +43.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
16 Sept 2026Wells FargoMaintainsOverweight$79 → $86
10 Sept 2026WedbushReiteratesOutperform$100
2 Sept 2026WedbushMaintainsOutperform—
2 Sept 2026WedbushMaintainsOutperform$88 → $100
6 Aug 2026HC Wainwright & Co.MaintainsBuy$118 → $120
6 Aug 2026HC Wainwright & Co.MaintainsBuy—
16 June 2026Morgan StanleyMaintainsOverweight—
16 June 2026Morgan StanleyMaintainsOverweight$80 → $85
10 June 2026WedbushReiteratesOutperform—
10 June 2026WedbushReiteratesOutperform$88
14 May 2026Morgan StanleyMaintainsOverweight—
2 Mar 2026Wells FargoMaintainsOverweight—
27 Feb 2026Truist SecuritiesMaintainsBuy—
17 Feb 2026BMO CapitalMaintainsOutperform—
17 Feb 2026Cantor FitzgeraldMaintainsOverweight—
17 Feb 2026StifelMaintainsBuy—
17 Feb 2026WedbushMaintainsOutperform—
17 Feb 2026Wells FargoMaintainsOverweight—
16 Dec 2025Wells FargoMaintainsOverweight—
10 Nov 2025Truist SecuritiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IRON appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

IRON vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Disc Medicine, Inc. returned +11.0% against +16.3% for the S&P 500, dividends included.

IRON vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150Oct 25Jan 26Apr 26Jul 26IRONS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IRON analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
8
Analysts cutting
0
Fundamentals

Disc Medicine, Inc. (IRON) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
5.0×

Cheaper than 66% of US stocks

Price / sales
—
Price / book
4.1×

Cheaper than 24% of US stocks

EV / EBITDA
−7.5×

Cheaper than 82% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−39.1%

Higher than 24% of US stocks

Return on assets
−24.0%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Disc Medicine, Inc. (IRON) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Disc Medicine, Inc. has a market value of $2.7B and an enterprise value of $2.0B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$245.9M.

  • Free cash flow in the twelve months to 30 June 2026: −$197.6M.

  • Shares outstanding: 38.3M.

  • Trailing P/E: 5.0×; forward P/E: −9.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Disc Medicine, Inc. employs 165 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

IRON vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IRONDisc Medicine, Inc.$2.7B
38
NAMSNewAmsterdam Pharma Co. NV$2.6B
39
NRIXNurix Therapeutics, Inc.$2.6B
39
BRVEBraveheart Bio, Inc.$2.6B
0
IMNMImmunome, Inc.$2.6B
32
BEAMBeam Therapeutics, Inc.$2.5B
50
ATAIAtai Beckley, Inc.$2.7B
—

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Disc Medicine, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IRON news & analysis

Disc Medicine, Inc. (IRON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 14 Sept 2026neutral

Disc Medicine, Inc. (IRON) presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation published by Seeking Alpha. The presentation covers the company's updates at the healthcare conference.

Why it matters — IRON watchers would care because the presentation gives insight into how the company communicates its pipeline and strategy to the investment community at a major healthcare conference.

Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting

GlobeNewsWire · 9 Sept 2026positive

Disc Medicine presented positive initial results from its RESTORE-PV Phase 2 trial of DISC-3405 in patients with polycythemia vera at the 2026 SOHO annual meeting. The data showed that treatment increased hepcidin and lowered serum iron, leading to reduced phlebotomy, controlled hematocrit, and improved symptom burden, with an oral presentation scheduled for the following day. The company also presented encore results from the Phase 2 RALLY-MF trial of selcodebart and a systematic literature review on the humanistic burden of anemia in myelofibrosis.

Why it matters — These initial Phase 2 results for DISC-3405 represent an important clinical milestone for Disc Medicine's pipeline in polycythemia vera, alongside supporting data for its myelofibrosis programs.

Disc Medicine to Participate in Upcoming Investor Conferences

GlobeNewsWire · 2 Sept 2026neutral

Disc Medicine, Inc. announced that its management will participate in fireside chats at four upcoming investor conferences. The company is a clinical-stage biopharmaceutical firm focused on treatments for serious hematologic diseases.

Why it matters — This news shows that IRON management is engaging with the investment community at multiple upcoming conferences, offering visibility into the company's development efforts.

Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

GlobeNewsWire · 31 Aug 2026positive

Disc Medicine announced it will present data from multiple clinical programs at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting in Houston, Texas, September 9-12, including an oral presentation of initial data from the RESTORE-PV trial of DISC-3405 in patients with polycythemia vera.

Why it matters — The presentation of initial RESTORE-PV data highlights progress in a key clinical program for IRON watchers tracking the company's pipeline.

FAQ

Frequently asked questions about IRON stock

What is the IRON stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Disc Medicine, Inc. have a median 12-month price target of $100, with estimates ranging from $83 to $128. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IRON stock a buy right now?

Of the 13 analysts covering Disc Medicine, Inc., 13 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Disc Medicine, Inc. 38 out of 100 across roughly 4,600 US stocks as at 18 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IRON?

As at 18 Sept 2026, Disc Medicine, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (67 of 100).

Will IRON stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +43.8% from the last close, and Ticker Nerd's factor model ranks Disc Medicine, Inc. 38 out of 100 as at 18 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IRON stock forecast for 2030?

No analyst covering Disc Medicine, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IRON are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $83 to $128 over the next 12 months.

How has IRON stock performed over the past year?

Disc Medicine, Inc. returned +11.0% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Disc Medicine, Inc. do?

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases.

What is the latest news on IRON?

The most recent item we track (Seeking Alpha, 14 Sept 2026): "Disc Medicine, Inc. (IRON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript". Disc Medicine, Inc. (IRON) presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation published by Seeking Alpha. The presentation covers the company's updates at the healthcare conference.

Company

About Disc Medicine, Inc.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. The company’s work centers on red blood cell biology, with programs designed to address disorders involving heme biosynthesis and iron homeostasis. Its current pipeline includes therapies in development for rare blood diseases such as erythropoietic porphyrias, Diamond-Blackfan anemia, anemia associated with myelofibrosis, and polycythemia vera. Disc Medicine operates as a research-driven biotech business, advancing both clinical and preclinical candidates aimed at modifying fundamental biological pathways rather than offering broad commercial products. Headquartered in Watertown, Massachusetts, Disc Medicine plays a specialized role in the hematology market by concentrating on diseases with significant unmet medical need and limited treatment options.

CEO Dr. John D. Quisel Esq., J.D., Ph.D. · 165 employees · United States · https://www.discmedicine.com